Immunai CTO and Co-Founder Luis Voloch on Using Deep Learning to Develop New Drugs - Ep. 176

Immunai CTO and Co-Founder Luis Voloch on Using Deep Learning to Develop New Drugs - Ep. 176

0 Umsagnir
0
Episode
174 of 287
Lengd
27Mín.
Tungumál
enska
Gerð
Flokkur
Óskáldað efni

What if we could map our immune system to create drugs that can help our bodies win the fight against cancer and other diseases? That’s the big idea behind immunotherapy. The problem: the immune system is incredibly complex.

Enter Immunai, a biotechnology company that’s using AI technology to map the human immune system and speed the development of new immunotherapies against cancer and autoimmune diseases.

On this episode of NVIDIA’s AI Podcast, host Noah Kravitz spoke with Luis Voloch, CTO and Co-Founder of Immunai, about tackling the challenges of the immune system with a machine learning and data science mindset.


Hlustaðu og lestu

Stígðu inn í heim af óteljandi sögum

  • Lestu og hlustaðu eins mikið og þú vilt
  • Þúsundir titla
  • Getur sagt upp hvenær sem er
  • Engin skuldbinding
Prófa frítt
is Device Banner Block 894x1036
Cover for Immunai CTO and Co-Founder Luis Voloch on Using Deep Learning to Develop New Drugs - Ep. 176

Other podcasts you might like ...